远程医疗公司Hims & Hers Health Inc.（HIMS）今日盘后股价大跌5.25%，引发市场广泛关注。
消息面上，公司发布了第二季度财报。尽管营收表现亮眼，达到7.53亿美元，超出市场预期的约7.00亿美元，同比增长约23.9%，但盈利指标大幅不及预期。公司第二季度每股亏损0.37美元，远高于市场预期的每股亏损0.03美元，与去年同期每股盈利0.17美元相比，业绩出现了显著恶化，由盈转亏。
盈利下滑的背后，是公司向品牌GLP-1减肥药转型所带来的压力。公司毛利率从去年同期的76%大幅下降至64%，国际业务拓展及减肥产品销售也对整体利润率形成了拖累。此外，向品牌减肥药的转型产生了约3300万美元的重组成本。尽管管理层上调了全年营收预期至31亿至33亿美元，并对国内业务下半年加速增长抱有信心，但巨额亏损仍然引发了投资者的担忧，导致盘后股价承压。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.